Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Subgroup Analyses of Effect of Treatment With Levodopa Inhalation Powder (CVT-301) 84mg by Severity of OFF Symptoms in People with Parkinson’s Disease, as Assessed by the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III)

Male MS Patients’ Safety, Tolerability and Efficacy Outcomes Do Not Differ from Female Patients Treated with Diroximel Fumarate: EVOLVE-MS-1 Ad-hoc Analysis